FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR “Nothing about us without us”: Why we’re working in partnership with... March 10, 2023 Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... January 2, 2025 Cancer in My Community: Bringing Palliative Care to People With Cancer... February 21, 2023 New on NCI’s Websites for March 2021 March 25, 2021 Load more HOT NEWS Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... Cancer in My Community: Working Toward Early Diagnosis for Children With... Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the...
